Advertisement

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

David A. Hyman, MD, JD, on Inclusive Shared Savings

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Deborah Collyar: What's In It for Patients?

Advertisement

Advertisement




Oct
08
Today In Oncology
HER2-Positive Breast Cancer FDA Approves Triplet for Maintenance Therapy
FDA Approves First-Line Pirtobrutinib for CLL-SLL
FDA Approves Lirafugratinib for Previously Treated, Unresectable, Locally Advanced or Metastatic Cholangiocarcinoma
FDA Approves New Labeling of ROS1 Inhibitor for NSCLC
Charles Perou 2026 William L. McGuire Memorial Lecture Award
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo